Injectable Artesunate Tools & Training
WHO recommends parenteral artesunate in preference to quinine and artemether for the treatment of severe P. falciparum malaria in adults and children. Intravenous (IV) injection is the preferred route of administration although intramuscular (IM) injection is also possible. To ensure that healthcare providers fully understand how to prepare and administer the product, these training materials were developed to illustrate these steps and facilitate correct use of the product.
65 health workers across 7 institutions in Kenya were interviewed to test these materials and to ensure they were well understood. New versions that incorporated lessons learned were tested daily in-situ over two weeks, to ensure that the final training materials better meet the needs of health personnel who treat patients with severe malaria. This project was carried out with continuous feedback from WHO GMP (Global Malaria Programme), MSF, Swiss TPH, PMI, MMV and CHAI.
New 2 vial injectable artesunate tool kit - English
The new Argesun® 60 mg injectable artesunate formulation for treating severe malaria simplifies preparation and administration, reducing errors and eliminating the need for dilution. It requires just a single reconstitution step with Arginine sodium bicarbonate, maintaining a concentration of 20 mg/mL for both intravenous and intramuscular use. By streamlining the process, this advancement enables quicker treatment initiation, which is critical for reducing high mortality rates associated with severe malaria.
Nouvelle trousse à outils pour injection d'artésunate à 2 flacons - French
La nouvelle formulation injectable d'artésunate Argesun® 60 mg pour le traitement du paludisme grave simplifie la préparation et l'administration, réduisant les erreurs et éliminant le besoin de dilution. Elle ne nécessite qu'une seule étape de reconstitution avec du bicarbonate de sodium d'arginine, maintenant une concentration de 20 mg/ml pour une utilisation intraveineuse et intramusculaire. En simplifiant le processus, cette avancée permet un démarrage plus rapide du traitement, ce qui est essentiel pour réduire les taux de mortalité élevés associés au paludisme grave.
